S&P 500   2,663.68 (+7.03%)
DOW   22,679.99 (+7.73%)
QQQ   196.48 (+7.15%)
AAPL   262.47 (+8.72%)
FB   165.55 (+7.37%)
MSFT   165.33 (+7.48%)
GOOGL   1,183.19 (+8.28%)
AMZN   1,997.59 (+4.77%)
CGC   14.34 (+8.23%)
NVDA   268.40 (+10.04%)
BABA   196.45 (+4.99%)
MU   46.37 (+12.49%)
GE   7.23 (+7.43%)
TSLA   516.24 (+7.55%)
AMD   47.52 (+11.58%)
T   29.44 (+7.21%)
ACB   0.80 (-1.24%)
F   4.53 (+6.84%)
NFLX   379.96 (+5.03%)
BAC   21.39 (+6.79%)
GILD   77.73 (-0.61%)
DIS   99.58 (+6.07%)
PRI   87.09 (+7.93%)
S&P 500   2,663.68 (+7.03%)
DOW   22,679.99 (+7.73%)
QQQ   196.48 (+7.15%)
AAPL   262.47 (+8.72%)
FB   165.55 (+7.37%)
MSFT   165.33 (+7.48%)
GOOGL   1,183.19 (+8.28%)
AMZN   1,997.59 (+4.77%)
CGC   14.34 (+8.23%)
NVDA   268.40 (+10.04%)
BABA   196.45 (+4.99%)
MU   46.37 (+12.49%)
GE   7.23 (+7.43%)
TSLA   516.24 (+7.55%)
AMD   47.52 (+11.58%)
T   29.44 (+7.21%)
ACB   0.80 (-1.24%)
F   4.53 (+6.84%)
NFLX   379.96 (+5.03%)
BAC   21.39 (+6.79%)
GILD   77.73 (-0.61%)
DIS   99.58 (+6.07%)
PRI   87.09 (+7.93%)
S&P 500   2,663.68 (+7.03%)
DOW   22,679.99 (+7.73%)
QQQ   196.48 (+7.15%)
AAPL   262.47 (+8.72%)
FB   165.55 (+7.37%)
MSFT   165.33 (+7.48%)
GOOGL   1,183.19 (+8.28%)
AMZN   1,997.59 (+4.77%)
CGC   14.34 (+8.23%)
NVDA   268.40 (+10.04%)
BABA   196.45 (+4.99%)
MU   46.37 (+12.49%)
GE   7.23 (+7.43%)
TSLA   516.24 (+7.55%)
AMD   47.52 (+11.58%)
T   29.44 (+7.21%)
ACB   0.80 (-1.24%)
F   4.53 (+6.84%)
NFLX   379.96 (+5.03%)
BAC   21.39 (+6.79%)
GILD   77.73 (-0.61%)
DIS   99.58 (+6.07%)
PRI   87.09 (+7.93%)
S&P 500   2,663.68 (+7.03%)
DOW   22,679.99 (+7.73%)
QQQ   196.48 (+7.15%)
AAPL   262.47 (+8.72%)
FB   165.55 (+7.37%)
MSFT   165.33 (+7.48%)
GOOGL   1,183.19 (+8.28%)
AMZN   1,997.59 (+4.77%)
CGC   14.34 (+8.23%)
NVDA   268.40 (+10.04%)
BABA   196.45 (+4.99%)
MU   46.37 (+12.49%)
GE   7.23 (+7.43%)
TSLA   516.24 (+7.55%)
AMD   47.52 (+11.58%)
T   29.44 (+7.21%)
ACB   0.80 (-1.24%)
F   4.53 (+6.84%)
NFLX   379.96 (+5.03%)
BAC   21.39 (+6.79%)
GILD   77.73 (-0.61%)
DIS   99.58 (+6.07%)
PRI   87.09 (+7.93%)
Log in

NASDAQ:AMRNAmarin Stock Price, Forecast & News

$4.80
+0.02 (+0.42 %)
(As of 04/6/2020 04:00 PM ET)
Add
Compare
Today's Range
$4.52
Now: $4.80
$5.10
50-Day Range
$4.00
MA: $12.95
$18.19
52-Week Range
$3.95
Now: $4.80
$26.12
Volume24.05 million shs
Average Volume12.68 million shs
Market Capitalization$1.71 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.18
Amarin Corp. Plc is a biopharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. Its product development program leverages its experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. It has developed and markets Vascepa capsules through wholesale. The company was founded by Geoffrey W. Guy on March 1, 1989 and is headquartered in Dublin, Ireland.
Read More
Amarin logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.3Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.68 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AMRN
CUSIPN/A
Phone353-1669-9020

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$429.76 million
Book Value$1.64 per share

Profitability

Net Income$-22,650,000.00

Miscellaneous

EmployeesN/A
Market Cap$1.71 billion
Next Earnings Date5/6/2020 (Estimated)
OptionableOptionable

Receive AMRN News and Ratings via Email

Sign-up to receive the latest news and ratings for AMRN and its competitors with MarketBeat's FREE daily newsletter.


Amarin (NASDAQ:AMRN) Frequently Asked Questions

How has Amarin's stock been impacted by COVID-19 (Coronavirus)?

Amarin's stock was trading at $12.56 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, AMRN shares have decreased by 61.8% and is now trading at $4.80. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Amarin?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amarin in the last year. There are currently 5 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Amarin.

When is Amarin's next earnings date?

Amarin is scheduled to release its next quarterly earnings announcement on Wednesday, May 6th 2020. View our earnings forecast for Amarin.

How were Amarin's earnings last quarter?

Amarin Co. plc (NASDAQ:AMRN) posted its quarterly earnings results on Tuesday, February, 25th. The biopharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.02) by $0.04. The biopharmaceutical company had revenue of $143.28 million for the quarter, compared to analysts' expectations of $137.70 million. Amarin had a negative net margin of 5.27% and a negative return on equity of 6.44%. Amarin's quarterly revenue was up 85.3% on a year-over-year basis. During the same period last year, the firm earned ($0.09) EPS. View Amarin's earnings history.

What guidance has Amarin issued on next quarter's earnings?

Amarin updated its FY 2020 After-Hours earnings guidance on Tuesday, February, 25th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $650-700 million, compared to the consensus revenue estimate of $695.43 million.

What price target have analysts set for AMRN?

12 analysts have issued 12 month price objectives for Amarin's stock. Their forecasts range from $4.00 to $51.00. On average, they anticipate Amarin's share price to reach $20.67 in the next twelve months. This suggests a possible upside of 330.6% from the stock's current price. View analysts' price targets for Amarin.

What are Wall Street analysts saying about Amarin stock?

Here are some recent quotes from research analysts about Amarin stock:
  • 1. According to Zacks Investment Research, "Amarin reported encouraging fourth-quarter results, wherein both earnings and sales beat estimates. Amarin’s sole marketed drug Vascepa has been on a strong growth trajectory for the last four years. The drug’s recent label expansion for cardiovascular indication looks promising. The growth trend for Vascepa is expected to continue in 2020. The company is expanding its sales force and start promotional programs to create awareness for Vascepa’s expanded label. These initiatives are likely to drive sales higher. The company is looking to get approval for the drug in additional countries. However, Amarin is over-dependent on Vascepa for its growth. Any setback to its commercialization plans will have an unfavorable impact. Competition is also rising in the targeted market. Shares have underperformed the industry in the past year." (3/5/2020)
  • 2. HC Wainwright analysts commented, "Our PT of $51 is based on equally weighted average of: (a) $47.99/share, as a 25x multiple of taxed and diluted FY29 GAAP EPS of $5.45 discounted back to and (b) an NPV of $53.14/share (discount rate 10%, growth rate 2%). Risks to our investment thesis and target price include: (1) Vascepa commercial ramp-up and/or peak sales not meeting our projections; and (2) further competitive disruption of the omega-3 market by branded drugs or generics and/ or OTC supplements beyond our model." (8/1/2019)

Has Amarin been receiving favorable news coverage?

Media stories about AMRN stock have been trending very negative this week, according to InfoTrie Sentiment. InfoTrie identifies positive and negative media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Amarin earned a news impact score of -3.3 on InfoTrie's scale. They also gave headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the next few days. View the latest news aboutAmarin.

Who are some of Amarin's key competitors?

What other stocks do shareholders of Amarin own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amarin investors own include Micron Technology (MU), Advanced Micro Devices (AMD), NVIDIA (NVDA), Canopy Growth (CGC), Alibaba Group (BABA), Square (SQ), Exelixis (EXEL), Novavax (NVAX), Bank of America (BAC) and Gilead Sciences (GILD).

Who are Amarin's key executives?

Amarin's management team includes the following people:
  • John F. Thero, President, Chief Executive Officer & Director
  • Derek Kalinowski, SVP-Manufacturing Operations
  • Michael W. Kalb, Chief Financial Officer & Senior Vice President
  • Steven B. Ketchum, Chief Scientific Officer & Senior Vice President
  • Craig B. Granowitz, Chief Medical Officer

What is Amarin's stock symbol?

Amarin trades on the NASDAQ under the ticker symbol "AMRN."

How do I buy shares of Amarin?

Shares of AMRN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Amarin's stock price today?

One share of AMRN stock can currently be purchased for approximately $4.80.

How big of a company is Amarin?

Amarin has a market capitalization of $1.71 billion and generates $429.76 million in revenue each year. The biopharmaceutical company earns $-22,650,000.00 in net income (profit) each year or ($0.07) on an earnings per share basis.  View additional information about Amarin.

What is Amarin's official website?

The official website for Amarin is http://www.amarincorp.com/.

How can I contact Amarin?

Amarin's mailing address is 77 Sir John Rogerson`s Quay Block C Grand Canal Docklands, Dublin L2, Dublin 2. The biopharmaceutical company can be reached via phone at 353-1669-9020 or via email at [email protected]

This page was last updated on 4/6/2020 by MarketBeat.com Staff

Featured Article: Coverage Ratio

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel